Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AHR | P35869 | 6/20 | 0.60 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | F10 | P00742 | 1/20 | 0.44 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.43 |
| ▸ | PTGES | O14684 | 1/20 | 0.41 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.41 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.41 |
| ▸ | FGFR4 | P22455 | 2/20 | 0.40 |
| ▸ | MAPKAPK2 | P49137 | 1/20 | 0.40 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.40 |
| ▸ | EPAS1 | Q99814 | 1/20 | 0.40 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.40 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.40 |
| ▸ | DEGS1 | O15121 | 1/20 | 0.39 |
| ▸ | GCK | P35557 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26086682 | 1.00 | AHR (0.60) | AHRGAAF10PTGS1PTGES | |
| SCHEMBL26419331 | 1.00 | AHR (0.60) | AHRGAAF10PTGS1PTGES | |
| SCHEMBL26419348 | 0.87 | AHR (0.63) | AHRHCRTR1 | |
| SCHEMBL26086770 | 0.87 | AHR (0.63) | AHRHCRTR1 | |
| SCHEMBL26088078 | 0.87 | AHR (0.66) | AHRF10 | |
| SCHEMBL30345457 | 0.87 | AHR (0.66) | AHRF10 | |
| SCHEMBL26419344 | 0.87 | AHR (0.63) | AHRHCRTR1 | |
| SCHEMBL26419319 | 0.87 | AHR (0.66) | AHRF10 | |
| SCHEMBL26419324 | 0.87 | AHR (0.66) | AHRF10 | |
| SCHEMBL30972573 | 0.81 | GAA (0.43) | AHRGAAF10PTGS1PTGES |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12037322-B2 | AHR agonists | ELI LILLY AND COMPANY (US) | 2024-07-16 | — | — | US | disclosed |
| US-12037322-B2 | AHR agonists | ELI LILLY AND COMPANY (US) | 2024-07-16 | — | — | US | disclosed |
| US-20230127797-A1 | AHR AGONISTS | ELI LILLY AND COMPANY | 2023-04-27 | — | — | US | disclosed |
| US-20230127797-A1 | AHR AGONISTS | ELI LILLY AND COMPANY | 2023-04-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12037322-B2 | AHR agonists | AHR, ARNT, RORC | AHR 1/4885GAA 3710/4885F10 4797/4885 |
| US-20230127797-A1 | AHR AGONISTS | AHR, ARNT, RORC | AHR 1/4885GAA 3710/4885F10 4797/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.